CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 41 enrolled
Drug / intervention
GZ21Tdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06888362
NCT06888362Phase 1Completed
CompareCT.gov

A Double-blind, Randomised, Placebo-controlled Phase I Trial to Investigate Safety, Tolerability and Pharmacokinetics of Single Ascending Topical Doses of GZ21T in Healthy Volunteers

Genzada Pharmaceuticals USA, Inc.·interventional·Posted Mar 21, 2025·Updated Jan 28, 2026

In Brief

A Phase 1 clinical trial evaluating GZ21T for Actinic Keratosis. Completed, enrolled 41 participants across 1 site.

Detailed Summary

This is a double-blind, randomised, placebo-controlled trial designed to evaluate safety, tolerability, and pharmacokinetics (PK) after topical administration of single ascending doses of GZ21T in healthy volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesSweden
CollaboratorsCTC Clinical Trial Consultants AB

Timeline

Phase 1CompletedFinished
20252026
First PostedMar 21, 2025
Enrollment StartAug 19, 2024
Primary CompletionMar 31, 2025
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 1.3 years ago

Interventions

GZ21Tdrug

GZ21T cream is intended to be studied as a potential treatment for patients with actinic keratoses and other dermatologic conditions which may be amendable to the study treatment.